← Eichor
Study identifier: NCT04055818 Synced from ClinicalTrials.gov · July 29, 2026
● Recruiting

A Study of Nicotinamide With Oral Tetrahydrouridine and Decitabine to Treat High Risk Sickle Cell Disease

Condition: Sickle Cell Disease  ·  Sponsor: EpiDestiny, Inc.

PhasePhase 1
Planned participants20
Who can joinAll sexes, 18 Years to no upper limit
Healthy volunteersNo

About this study

A randomized control trial in 20 subjects with sickle cell disease comparing oral THU-decitabine to nicotinamide and in combination (THU, decitabine and nicotinamide).

This description comes directly from the study's public registry record.

Talk to the study team

Lani Krauz  ·  312-413-0242  ·  LIgnacio@UIC.EDU

Always discuss trial participation with your own doctor first.

Locations (1)

University of Illinois at Chicago College of MedicineChicago, Illinois, United StatesRecruiting

Follow this study

Get one email when the public record changes — results posted, or the study's status changes. Nothing else, ever.

We email about this public record only. Unsubscribe anytime with one click. Never medical advice.

Is this your study? This page was generated automatically from the public registry record. Sponsors can claim it — free — to add branding and verified contact routing. Claim this page →

This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.

Source record: clinicaltrials.gov/study/NCT04055818